{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:41:31Z","timestamp":1761561691060,"version":"3.40.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s11239-012-0814-7","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T19:53:20Z","timestamp":1350503600000},"page":"31-41","source":"Crossref","is-referenced-by-count":14,"title":["Elevating local concentrations of GPIIb\u2013IIIa antagonists counteracts platelet thrombus stability"],"prefix":"10.1007","volume":"36","author":[{"given":"Henry E.","family":"Speich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey T.","family":"Lands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"issue":"3 Suppl","key":"814_CR1","doi-asserted-by":"crossref","first-page":"4A","DOI":"10.1016\/j.amjcard.2008.11.017","volume":"103","author":"LK Jennings","year":"2009","unstructured":"Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103(3 Suppl):4A\u201310A. doi: 10.1016\/j.amjcard.2008.11.017","journal-title":"Am J Cardiol"},{"issue":"25","key":"814_CR2","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1161\/01.CIR.98.25.2829","volume":"98","author":"DF Kong","year":"1998","unstructured":"Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ (1998) Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb\/IIIa integrin in ischemic heart disease. Circulation 98(25):2829\u20132835","journal-title":"Circulation"},{"issue":"1","key":"814_CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/eurheartj\/ehn480","volume":"30","author":"P Ortolani","year":"2009","unstructured":"Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall\u2019Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A (2009) Long-term effectiveness of early administration of glycoprotein IIb\/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 30(1):33\u201343. doi: 10.1093\/eurheartj\/ehn480","journal-title":"Eur Heart J"},{"issue":"9148","key":"814_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","volume":"353","author":"EJ Topol","year":"1999","unstructured":"Topol EJ, Byzova TV, Plow EF (1999) Platelet GPIIb\u2013IIIa blockers. Lancet 353(9148):227\u2013231. doi: 10.1016\/S0140-6736(98)11086-3","journal-title":"Lancet"},{"issue":"5","key":"814_CR5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0735-1097(00)00554-4","volume":"35","author":"AM Lincoff","year":"2000","unstructured":"Lincoff AM, Califf RM, Topol EJ (2000) Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 35(5):1103\u20131115","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"814_CR6","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2008-06-077891","volume":"112","author":"BS Coller","year":"2008","unstructured":"Coller BS, Shattil SJ (2008) The GPIIb\/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112(8):3011\u20133025. doi: 10.1182\/blood-2008-06-077891","journal-title":"Blood"},{"issue":"1","key":"814_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.ATV.21.1.142","volume":"21","author":"JP Collet","year":"2001","unstructured":"Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C (2001) Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21(1):142\u2013148","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"814_CR8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0037-1613127","volume":"87","author":"SJ Marciniak Jr","year":"2002","unstructured":"Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87(6):1020\u20131025","journal-title":"Thromb Haemost"},{"issue":"4","key":"814_CR9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/hh0402.105095","volume":"90","author":"JP Collet","year":"2002","unstructured":"Collet JP, Montalescot G, Lesty C, Weisel JW (2002) A structural and dynamic investigation of the facilitating effect of glycoprotein IIb\/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 90(4):428\u2013434","journal-title":"Circ Res"},{"issue":"4","key":"814_CR10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","volume":"41","author":"M Moser","year":"2003","unstructured":"Moser M, Bertram U, Peter K, Bode C, Ruef J (2003) Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41(4):586\u2013592","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"814_CR11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2004.02.059","volume":"44","author":"S Goto","year":"2004","unstructured":"Goto S, Tamura N, Ishida H (2004) Ability of anti-glycoprotein IIb\/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44(2):316\u2013323","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"814_CR12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1538-7836.2009.03432.x","volume":"7","author":"HE Speich","year":"2009","unstructured":"Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK (2009) Variability of platelet aggregate dispersal with glycoprotein IIb\u2013IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 7(6):983\u2013991. doi: 10.1111\/j.1538-7836.2009.03432.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"814_CR13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)29562-8","volume":"297","author":"MJ Quinn","year":"2001","unstructured":"Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ (2001) Occupancy of the internal and external pools of glycoprotein IIb\/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 297(2):496\u2013500","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"814_CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","volume":"71","author":"R Robson","year":"2002","unstructured":"Robson R, White H, Aylward P, Frampton C (2002) Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 71(6):433\u2013439. doi: 10.1067\/mcp.2002.124522","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"814_CR15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00003088-200342080-00001","volume":"42","author":"IC Gilchrist","year":"2003","unstructured":"Gilchrist IC (2003) Platelet glycoprotein IIb\/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet 42(8):703\u2013720","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"814_CR16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0149-2918(04)90034-3","volume":"26","author":"DD Gretler","year":"2004","unstructured":"Gretler DD, Guerciolini R, Williams PJ (2004) Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 26(3):390\u2013398","journal-title":"Clin Ther"},{"issue":"3","key":"814_CR17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1213\/01.ane.0000226098.95698.0f","volume":"103","author":"A Koster","year":"2006","unstructured":"Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, Lincoff MA (2006) Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the \u201cEVOLUTION OFF\u201d trial. Anesth Analg 103(3):540\u2013544. doi: 10.1213\/01.ane.0000226098.95698.0f","journal-title":"Anesth Analg"},{"issue":"1","key":"814_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11239-006-7454-8","volume":"22","author":"AJ Deibele","year":"2006","unstructured":"Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, Gibson CM (2006) Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 22(1):47\u201350. doi: 10.1007\/s11239-006-7454-8","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"814_CR19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11239-008-0243-9","volume":"28","author":"B Cortese","year":"2009","unstructured":"Cortese B, Picchi A, Micheli A, Limbruno U (2009) Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder? J Thromb Thrombolysis 28(1):74\u201376. doi: 10.1007\/s11239-008-0243-9","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"814_CR20","doi-asserted-by":"crossref","first-page":"C1045","DOI":"10.1152\/ajpcell.90644.2007","volume":"295","author":"HE Speich","year":"2008","unstructured":"Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, Jennings LK (2008) Platelets undergo phosphorylation of Syk at Y525\/526 and Y352 in response to pathophysiological shear stress. Am J Physiol Cell Physiol 295(4):C1045\u2013C1054","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3 SUPPL.","key":"814_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/1054-8807(93)90043-2","volume":"2","author":"SM Slack","year":"1993","unstructured":"Slack SM, Turitto VT (1993) Chapter 2 Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol 2(3 SUPPL.):11\u201321","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"814_CR22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1055\/s-0038-1648957","volume":"72","author":"SM Slack","year":"1994","unstructured":"Slack SM, Turitto VT (1994) Flow chambers and their standardization for use in studies of thrombosis. On behalf of the subcommittee on rheology of the scientific and standardization committee of the ISTH. Thromb Haemost 72(5):777\u2013781","journal-title":"Thromb Haemost"},{"issue":"3","key":"814_CR23","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/1054-8807(93)90043-2","volume":"2","author":"SM Slack","year":"1993","unstructured":"Slack SM, Turitto VT (1993) Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol 2(3):S11\u2013S21","journal-title":"Cardiovasc Pathol"},{"issue":"19","key":"814_CR24","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1161\/01.CIR.103.19.2328","volume":"103","author":"JP Collet","year":"2001","unstructured":"Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, Drobinski G, Soria C, Pinton P, Barragan P, Thomas D (2001) Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 103(19):2328\u20132331","journal-title":"Circulation"},{"key":"814_CR25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1749-6632.2001.tb03521.x","volume":"936","author":"JS Bennett","year":"2001","unstructured":"Bennett JS (2001) Platelet-fibrinogen interactions. Ann N Y Acad Sci 936:340\u2013354","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"814_CR26","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1074\/jbc.274.8.4633","volume":"274","author":"DD Hu","year":"1999","unstructured":"Hu DD, White CA, Panzer-Knodle S, Page JD, Nicholson N, Smith JW (1999) A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3. J Biol Chem 274(8):4633\u20134639","journal-title":"J Biol Chem"},{"issue":"3","key":"814_CR27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2005.05782.x","volume":"131","author":"M Frojmovic","year":"2005","unstructured":"Frojmovic M, Labarthe B, Legrand C (2005) Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban. Br J Haematol 131(3):348\u2013355","journal-title":"Br J Haematol"},{"issue":"4","key":"814_CR28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1083\/jcb.200801146","volume":"182","author":"TA Springer","year":"2008","unstructured":"Springer TA, Zhu J, Xiao T (2008) Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol 182(4):791\u2013800. doi: 10.1083\/jcb.200801146","journal-title":"J Cell Biol"},{"issue":"43","key":"814_CR29","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/bi1009858","volume":"49","author":"RR Hantgan","year":"2010","unstructured":"Hantgan RR, Stahle MC, Lord ST (2010) Dynamic regulation of fibrinogen: integrin alphaIIbbeta3 binding. Biochemistry 49(43):9217\u20139225. doi: 10.1021\/bi1009858","journal-title":"Biochemistry"},{"issue":"36","key":"814_CR30","doi-asserted-by":"crossref","first-page":"13114","DOI":"10.1073\/pnas.0404201101","volume":"101","author":"A Artoni","year":"2004","unstructured":"Artoni A, Li J, Mitchell B, Ruan J, Takagi J, Springer TA, French DL, Coller BS (2004) Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA 101(36):13114\u201313120. doi: 10.1073\/pnas.04042011010404201101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"814_CR31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/B:THRO.0000003308.63022.8d","volume":"15","author":"K Schror","year":"2003","unstructured":"Schror K, Weber AA (2003) Comparative pharmacology of GP IIb\/IIIa antagonists. J Thromb Thrombolysis 15(2):71\u201380","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"814_CR32","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1182\/blood-2006-10-054015","volume":"109","author":"M Jirouskova","year":"2007","unstructured":"Jirouskova M, Jaiswal JK, Coller BS (2007) Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading. Blood 109(12):5260\u20135269. doi: 10.1182\/blood-2006-10-054015","journal-title":"Blood"},{"issue":"1","key":"814_CR33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0021-9258(19)86278-6","volume":"255","author":"GA Marguerie","year":"1980","unstructured":"Marguerie GA, Edgington TS, Plow EF (1980) Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 255(1):154\u2013161","journal-title":"J Biol Chem"},{"issue":"2","key":"814_CR34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2006-07-028282","volume":"109","author":"MJ Maxwell","year":"2007","unstructured":"Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP (2007) Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 109(2):566\u2013576. doi: 10.1182\/blood-2006-07-028282","journal-title":"Blood"},{"issue":"6","key":"814_CR35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nm.1955","volume":"15","author":"WS Nesbitt","year":"2009","unstructured":"Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP (2009) A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 15(6):665\u2013673. doi: 10.1038\/nm.1955","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"814_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1538-7836.2009.03401.x","volume":"7","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Nesbitt WS, Westein E (2009) Dynamics of platelet thrombus formation. J Thromb Haemost 7(Suppl 1):17\u201320. doi: 10.1111\/j.1538-7836.2009.03401.x","journal-title":"J Thromb Haemost"},{"issue":"6","key":"814_CR37","first-page":"1149","volume":"102","author":"IC Munnix","year":"2009","unstructured":"Munnix IC, Cosemans JM, Auger JM, Heemskerk JW (2009) Platelet response heterogeneity in thrombus formation. Thromb Haemost 102(6):1149\u20131156. doi: 10.1160\/TH09-05-0289","journal-title":"Thromb Haemost"},{"issue":"19","key":"814_CR38","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/eurheartj\/ehi293","volume":"26","author":"U Zeymer","year":"2005","unstructured":"Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, Seidl K, Schroder R, Schneider S, Senges J (2005) Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26(19):1971\u20131977","journal-title":"Eur Heart J"},{"issue":"8","key":"814_CR39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0002-9149(03)00983-4","volume":"92","author":"DE Cutlip","year":"2003","unstructured":"Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, Giri S, Caputo RP (2003) Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92(8):977\u2013980","journal-title":"Am J Cardiol"},{"issue":"23","key":"814_CR40","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ehj.2004.09.018","volume":"25","author":"M Gyongyosi","year":"2004","unstructured":"Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hodl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K (2004) Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion\u2014results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 25(23):2125\u20132133","journal-title":"Eur Heart J"},{"issue":"10","key":"814_CR41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ehj.2004.04.003","volume":"25","author":"AW Hof van \u2018t","year":"2004","unstructured":"van \u2018t Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F (2004) Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b\/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25(10):837\u2013846","journal-title":"Eur Heart J"},{"issue":"5","key":"814_CR42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ahj.2005.07.026","volume":"150","author":"J Godicke","year":"2005","unstructured":"Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G (2005) Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 150(5):1015","journal-title":"Am Heart J"},{"issue":"6","key":"814_CR43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0706416","volume":"358","author":"T Svilaas","year":"2008","unstructured":"Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358(6):557\u2013567. doi: 10.1056\/NEJMoa0706416","journal-title":"N Engl J Med"},{"issue":"9628","key":"814_CR44","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(08)60833-8","volume":"371","author":"PJ Vlaar","year":"2008","unstructured":"Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F (2008) Cardiac death and reinfarction after 1\u00a0year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 371(9628):1915\u20131920. doi: 10.1016\/S0140-6736(08)60833-8","journal-title":"Lancet"},{"issue":"6","key":"814_CR45","first-page":"278","volume":"22","author":"PR Hansen","year":"2010","unstructured":"Hansen PR, Iversen A, Abdulla J (2010) Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 22(6):278\u2013282","journal-title":"J Invasive Cardiol"},{"issue":"9","key":"814_CR46","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.amjcard.2011.06.039","volume":"108","author":"S Friedland","year":"2011","unstructured":"Friedland S, Eisenberg MJ, Shimony A (2011) Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 108(9):1244\u20131251. doi: 10.1016\/j.amjcard.2011.06.039","journal-title":"Am J Cardiol"},{"issue":"9819","key":"814_CR47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","volume":"379","author":"H Thiele","year":"2012","unstructured":"Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379(9819):923\u2013931. doi: 10.1016\/S0140-6736(11)61872-2","journal-title":"Lancet"},{"issue":"9819","key":"814_CR48","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(12)60079-8","volume":"379","author":"OF Bertrand","year":"2012","unstructured":"Bertrand OF, Jolly S (2012) AIDA STEMI: no benefit for intracoronary abciximab. Lancet 379(9819):875\u2013877. doi: 10.1016\/S0140-6736(12)60079-8","journal-title":"Lancet"},{"issue":"9","key":"814_CR49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jcin.2010.05.017","volume":"3","author":"F Prati","year":"2010","unstructured":"Prati F, Capodanno D, Pawlowski T, Ramazzotti V, Albertucci M, La Manna A, Di Salvo M, Gil RJ, Tamburino C (2010) Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 3(9):928\u2013934. doi: 10.1016\/j.jcin.2010.05.017","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"814_CR50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ccd.22760","volume":"77","author":"AJ Deibele","year":"2011","unstructured":"Deibele AJ, Michael Gibson C (2011) Intracoronary delivery of eptifibatide with the ClearWay(R) RX infusion catheter. Catheter Cardiovasc Interv 77(2):222\u2013227. doi: 10.1002\/ccd.22760","journal-title":"Catheter Cardiovasc Interv"},{"key":"814_CR51","author":"GW Stone","year":"2012","unstructured":"Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. doi: 10.1001\/jama.2012.421","journal-title":"JAMA"},{"issue":"7","key":"814_CR52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2459\/JCM.0b013e3283341c1c","volume":"11","author":"G Sardella","year":"2010","unstructured":"Sardella G, Sangiorgi GM, Mancone M, Colantonio R, Donahue M, Politi L, Ducci CB, Carbone I, Francone M, Ligabue G, Fiocchi F, Di Roma A, Benedetti G, Lucisano L, Stio RE, Agati L, Modena MG, Genuini I, Fedele F, Gibson M (2010) A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J Cardiovasc Med (Hagerstown) 11(7):529\u2013535. doi: 10.2459\/JCM.0b013e3283341c1c","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"21","key":"814_CR53","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"GW Stone","year":"2006","unstructured":"Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203\u20132216. doi: 10.1056\/NEJMoa062437","journal-title":"N Engl J Med"},{"issue":"13","key":"814_CR54","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","volume":"295","author":"A Kastrati","year":"2006","unstructured":"Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295(13):1531\u20131538. doi: 10.1001\/jama.295.13.joc60034","journal-title":"JAMA"},{"issue":"6","key":"814_CR55","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jcin.2008.10.004","volume":"1","author":"AM Lincoff","year":"2008","unstructured":"Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW (2008) Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv 1(6):639\u2013648. doi: 10.1016\/j.jcin.2008.10.004","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-012-0814-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T11:25:01Z","timestamp":1744543501000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-012-0814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s11239-012-0814-7","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}